Search
Epratuzumab
go.drugbank.com/drugs/DB04958InvestigationalThis agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. … Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2).
Ramoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Alifedrine
go.drugbank.com/drugs/DB20853ExperimentalAlifedrine is a small molecule drug. The usage of the INN stem '-drine' in the name indicates that Alifedrine is a sympathomimetic. Alifedrine has a monoisotopic molecular weight of 289.2 Da.
Categories: Compounds used in a research, industrial, or household settingAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Acipimox is a niacin derivative used as a hypolipidemic agent.
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.
Iclaprim
go.drugbank.com/drugs/DB06358InvestigationalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalIt was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes. … ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).
Polydextrose
go.drugbank.com/drugs/DB14836ExperimentalPolydextrose is under investigation in clinical trial NCT02258750 (Assessing a Polydextrose Containing Soup on Food Intake, Appetite and Biomarkers of Satiation and Satiety).
Categories: Compounds used in a research, industrial, or household settingIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexMizolastine
go.drugbank.com/drugs/DB12523ApprovedMizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
Categories: Antihistamines for Systemic Use